decisionhealth Newsletters, Coder Pink Sheets - 2021 Issue 4 (April)
FDA issues emergency authorization for new COVID-19 antibody treatment
Subscribe or sign in to view the full article.
Article Overview
This premium article covers a FDA emergency use authorization for a COVID-19 antibody combination treatment and the related billing context for providers. It is relevant to coders, billers, reimbursement staff, and clinical practices that track CMS payment guidance for newly authorized therapies. The article also discusses the general settings, patient-use limitations, and HCPCS Level II reporting updates associated with the treatment.
Why This Topic Matters
Newly authorized COVID-19 therapies can affect billing, claims reporting, and reimbursement workflows quickly. Providers and coding staff need to know which HCPCS Level II codes apply and how CMS payment policy may align with the new treatment.
What You Will Learn
- The scope of a FDA emergency use authorization for a COVID-19 antibody combination
- How the article connects the authorization to Medicare reporting and payment considerations
- What general provider and patient-use limitations are associated with the treatment
- Which broad billing and reimbursement topics are addressed for newly authorized COVID-19 therapies
Who Should Read This
- Medical coders
- Billing specialists
- Reimbursement staff
- Revenue cycle teams
- Hospital outpatient departments
- Physician practices
- Pharmacy and infusion service teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com